Tonix Pharmaceuticals Holding Corp.
TNXP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TNXP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and infectious diseases, with a marketed product for fibromyalgia (TONMYA) and a pipeline including a Lyme disease vaccine candidate (TNX-4800).
Key risk: Cash runway limited
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials · 2 catalysts for Tonix Pharmaceuticals Holding Corp..
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and infectious diseases, with a marketed product for fibromyalgia (TONMYA) and a pipeline including a Lyme disease vaccine candidate (TNX-4800).
- Cash and equivalents of $176.6M as of 2026-06-30 [sec].
- Total revenue of $13.5M for the three months ended 2026-06-30, driven by TONMYA launch in November 2025 [sec_mda].
- Net loss of $40.6M for the three months ended 2026-06-30 [sec].
- Phase 2 readout for TNX-4800 (Lyme disease prevention) expected in 2026-12-31 [catalyst].
- Cash runway expected into early Q2 2027, but not extending 12 months from filing [sec_mda].
What works
- TONMYA (for fibromyalgia) generated $10.95M in revenue in Q2 2026, indicating early commercial traction [sec_mda].
- TNX-4800 (Lyme disease vaccine) has completed Phase 1 and a Type C meeting with FDA is scheduled for Q3 2026 to discuss Phase 2 design [sec].
- Cash position of $176.6M as of June 30, 2026 provides near-term operational runway into early Q2 2027 [sec_mda].
What to weigh
- Net loss of $40.6M for Q2 2026 and cumulative operating losses raise going-concern risks [sec].
- Cash runway only extends into early Q2 2027, requiring additional financing within 12 months [sec_mda].
- Phase 2 study for TNX-4800 has not yet started; FDA clearance and trial design are pending [sec].
- Patent/exclusivity expiry for TONMYA in 2034-03-14 may limit long-term revenue protection [catalyst].
Catalyst timeline
- 2026-12-31 · Phase2_Topline · tnx-4800 — Topline results from the Phase 2 study of TNX-4800 for seasonal prevention of Lyme disease.
- 2034-03-14 · Patent/Exclusivity Expiry: TONMYA — Patent or exclusivity protection for TONMYA (fibromyalgia) expires, potentially opening to generic competition.
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash resources expected into early Q2 2027, not covering 12 months from filing [sec_mda].
- Regulatory uncertainty for TNX-4800 — Phase 2 design pending FDA clearance; Type C meeting in Q3 2026 [sec].
- Patent expiry for TONMYA — Patent/exclusivity expiry on 2034-03-14 may affect long-term revenue [catalyst].
What to watch
- FDA Type C meeting outcome for TNX-4800 in Q3 2026 [sec].
- Phase 2 topline data for TNX-4800 expected in 2026-12-31 [catalyst].
- Cash burn rate and potential need for additional financing in 2027 [sec_mda].
- Commercial ramp of TONMYA and its impact on revenue growth [sec_mda].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Tonix Pharmaceuticals Holding Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tonix Pharmaceuticals Holding Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
13.1 months
D/E 0.14 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~123d
6 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
80
Total value held
$68.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,037,300 | $14.3M |
| blackrock, inc. | 968,177 | $13.3M |
| citadel advisors llc | 511,812 | $7.0M |
| geode capital management, llc | 313,291 | $4.3M |
| balyasny asset management l.p. | 313,082 | $4.3M |
| state street corp | 230,607 | $3.2M |
| millennium management llc | 219,673 | $3.0M |
| aqr capital management llc | 161,208 | $2.2M |
| susquehanna international group, llp | 157,979 | $2.2M |
| point72 asset management, l.p. | 125,414 | $1.7M |
Showing top 10 of 80 institutional holders of Tonix Pharmaceuticals Holding Corp.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 14.6%
- Days to cover
- 4.6
- Shares short
- 2,075,650
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TNXP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tonix Pharmaceuticals Holding Corp.?
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and infectious diseases, with a marketed product for fibromyalgia (TONMYA) and a pipeline including a Lyme disease vaccine candidate (TNX-4800).
What is Tonix Pharmaceuticals Holding Corp.'s next catalyst?
Tonix Pharmaceuticals Holding Corp.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: tnx-4800" — expected December 31, 2026.
Who is the CEO of Tonix Pharmaceuticals Holding Corp.?
Dr. Seth Lederman M.D. is the chief executive officer of Tonix Pharmaceuticals Holding Corp. (TNXP).
Where is Tonix Pharmaceuticals Holding Corp. headquartered?
Tonix Pharmaceuticals Holding Corp. (TNXP) is headquartered in Berkeley Heights, NJ, United States.
What therapeutic areas does Tonix Pharmaceuticals Holding Corp. focus on?
Tonix Pharmaceuticals Holding Corp. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.